News | November 09, 2025
Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025
Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Sprycel Tablets
_256_384.jpg)
The transaction is expected to be completed within one month from the signing of the definitive agreements.
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Subscribe To Our Newsletter & Stay Updated
